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Abstract
Background: High content immune profiling in peripheral blood may reflect immune aberrations associated with
inflammation in multiple sclerosis (MS) and other autoimmune diseases affecting the central nervous system.
Methods and Findings: Peripheral blood mononuclear cells from 46 patients with multiple sclerosis (MS), 9 patients
diagnosed with relapsing remitting MS (RRMS), 13 with secondary progressive multiple sclerosis (SPMS), 9 with other
neurological diseases (OND) and well as 15 healthy donors (HD) were analyzed by 12 color flow cytometry (TCRab, TCRcd,
CD4, CD8a, CD8b, CD45RA, CCR7, CD27, CD28, CD107a, CD127, CD14) in a cross-sectional study to identify variables
significantly different between controls (HD) and patients (OND, RRMS, SPMS). We analyzed 187 individual immune cell
subsets (percentages) and the density of the IL-7 receptor alpha chain (CD127) on 59 individual immune phenotypes using a
monoclonal anti-IL-7R antibody (clone R34.34) coupled to a single APC molecule in combination with an APC-bead array. A
non-parametric analysis of variance (Kruskal-Wallis test) was conducted in order to test for differences among the groups in
each of the variables. To correct for the multiplicity problem, the FDR correction was applied on the p-values. We identified
19 variables for immune cell subsets (percentages) which allowed to segregate healthy individuals and individuals with CNS
disorders. We did not observe differences in the relative percentage of IL-7R-positive immune cells in PBMCs. In contrast, we
identified significant differences in IL-7 density, measured on a single cell level, in 2/59 variables: increased numbers of
CD127 molecules on TCRab+CD4+CD25 (intermed) T-cells and on TCRab+CD4+CD252CD107a+ T-cells (mean: 28376 Il-7R
binding sites on cells from HD, 48515 in patients with RRMS, 38195 in patients with SPMS and 33692 IL-7 receptor binding
sites on cells from patients with OND).
Conclusion: These data show that immunophenotyping represents a powerful tool to differentiate healthy individuals from
individuals suffering from neurological diseases and that the number of IL-7 receptor molecules on differentiated
TCRab+CD4+CD252CD107a+ T-cells, but not the percentage of IL-7R-positive cells, segregates healthy individuals from
patients with neurological disorders.
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Introduction
Complex genetic traits and environmental factors [1] may
contribute to immune responses associated with multiple sclerosis
(MS), a demyelinating disease of the central nervous system
characterized by a wide clinical variability [2] More recent studies
addressed the question whether alterations in immune cell subsets in
the peripheral circulation contribute to and reflect CNS inflamma-
tion in patients with MS [3]. MRI-active and MRI-inactive patients
showed significant differences in the relative composition of several
immune cell subsets, including TCRab+CD4+CCR72CD45RA2
peripheral memory T-cells [3] and a reduction of CD8low+CD56+
natural killer cells [4]. Profiling immune cell subsets in peripheral
blood with an attempt to identify patterns associated with MS has
been carried out since more than 25 years [5]. The advent of high
content flow cytometric analysis enables now to look at a
comprehensive number of immune cell subsets simultaneously at
the single cell level. Most studies examined either the relative
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6534distribution or absolute numbers of immune cell subsets in PBMCs.
In contrast, the number of biologically relevant molecules, e.g.
CD127, the alpha chain of the IL-7 receptor, on single cells has not
yet been addressed: IL-7, signaling through the IL-7 receptor, has
been shown to increase antigen-specific T-cell responses in patients
with MS [6] and provide long-term T-cell survival and thymic
output [7], which may lead to the expansion of auto-reactive T-cell
clones [8]. We examined inthe currentreportthe percentage of 187
individual T-cell subsets for association with IL-7R expression. This
approach addresses differences in immune cell composition in
peripheral blood mononuclear cells (PBMCs), but it does not
measure differences of IL-7R expression on a single cell level. We
measured therefore CD127 antibody binding sites on a more
limited number of immune cell subsets (n=59) to objectively define
the number of IL-7R molecules on distinct T-cell phenotypes to
identify cellular markers associated with MS.
Results
Cluster analysis of immune phenotypes segregates
healthy blood donors from individuals with neurological
diseases
187 individual phenotypes (see supplementary Table S1, i.e.
S1.3) were measured to define the percentage of immune cell
subsets in peripheral blood mononuclear cells (PBMCs) from
Table 1. Clinical profile of patient enrolled in the study.
Sample ID Treatment Sex
Age at
sampling Diag:G1 Diag:G2 Diag:G3 Diagnosis EDSS
OB or Ig
Index MRI MRI lesions
P1 No F 31 MS RR RR-rem RRMS-rem 1 Yes Positive 9 or more
P2 No F 35 CIS CIS CIS-relaps CIS-Myelitis 3 Yes Positive 9 or more
P3 No F 30 MS RR RR-rem RRMS-rem 2 Yes Positive 3 to 5
P4 No F 39 OND OND OND Hypothyreosis and
sensory disturbance
1 No Normal 0
P5 No F 25 OND OND OND Paresthesia 0 No Normal 0
P6 No F 45 OND.INF OND.INF OND.INF Neuroborreliosis NA No Not done NA
P7 Simvastatin
Gabapentin
Atenolol
F 67 MS SP SPMS SPMS 3 Yes Positive 9 or more
P8 No F 39 OND.INF OND.INF OND.INF Reccurent Myelitis 3 No Normal 0
P9 No F 66 OND.INF OND.INF OND.INF Neuroinflammatory
symptoms, potential
side effects of earlier
anti-TNF treatment
NA Yes Atypical 3 to 5
P10 Betaferon F 36 MS RR RR-rem RRMS rem 1 No Atypical 9 or more
P11 No F 43 OND OND OND Paresthesia 0 No Normal 0
P12 No F 44 MS RR RR-rem MS 1.5 No Positive 9 or more
P13 No M 27 OND OND OND Parasthesia 1 No Not done NA
P14 Citalopram F 34 OND OND OND Carpal Tunnel
Syndrome
NA No Normal 0
P15 No F 55 CIS CIS CIS-rem CIS Supratentorial 2.5 Yes Positive 9 or more
P16 No F 31 MS RR RR-rem RRMS rem 0 LP not done Positive 6 to 8
P17 No M 59 MS SP SPMS SPMS 3.5 Yes NA NA
P18 No F 45 MS SP SPMS SPMS 4 Yes NA NA
P19 No M 51 MS SP SPMS SPMS 5.5 Yes NA NA
P20 No M 45 MS SP SPMS SPMS 6 Yes NA NA
P21 No F 60 MS SP SPMS SPMS 4.5 Yes NA NA
P22 No F 62 MS SP SPMS SPMS 6 Yes NA NA
P23 No F 57 MS SP SPMS SPMS 5.5 Yes NA NA
P24 No F 62 MS SP SPMS SPMS 6 Yes NA NA
P25 No M 54 MS SP SPMS SPMS 6 Yes NA NA
P26 No F 62 MS SP SPMS SPMS 5.5 Yes NA NA
P27 No M 43 MS SP SPMS SPMS 4 Yes NA NA
P28 No F 28 MS RR RR-rem RRMS rem 1.5 Yes Positive 9 or more
P29 No M 25 MS RR RR-rem RRMS rem 2 Yes Positive 9 or more
P30 No M 35 MS RR RR-rem RRMS rem 2.5 Yes Positive 9 or more
P31 No F 44 MS SP SPMS SPMS 3 Yes Positive 9 or more
NA=not applicable, rem=remittent.
doi:10.1371/journal.pone.0006534.t001
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PLoS ONE | www.plosone.org 2 August 2009 | Volume 4 | Issue 8 | e6534healthy individuals and in patients with neurological disorders
(Table 1), age and sex distribution for each individual group is
provided in Table 2. A Kruskal-Wallis test was conducted and p-
values were corrected using the FDR method. This resulted in 19
significant variables which differentiated healthy individuals and
individuals with neurological disorders (Figure 1). We performed a
heatmap analysis in order to visualize differences in the relative
distribution of immune cell subsets in PBMCs obtained from
healthy donors and from individuals with neurological diseases.
Analysis of PBMCs obtained from individual number 45, a
healthy donor, showed a very different pattern of immune cell
subsets as compared to the rest of the individuals. The statistical
testing and multiplicity correction were therefore run in two
different variants: including (Figure 2) and excluding individual
number 45 (Figure 3) from the statistical analysis. The significant 19
variables are listed with the corresponding p-values in heatmaps,
eachcolor represents a defined percentage of the target immune cell
populationinlymphocytes. It is evident that allphenotypic variables
(percentages of immune cell subsets) are slightly different in each
individual. In general, clustering the 19 different variables showed
that phenotypic markers, defined by flow cytometry, allow to
segregate healthy individuals from individuals with neurological
diseases. This exercise also confirmed the results that individual #
45 (a healthy blood donor) exhibited a different phenotypic pattern
in PBMCs (Figures 2 and 3), clinically very well defined populations
are crucial for the identification of markers which allow to identify
an individual as ‘healthy’ or suffering from a (inflammatory,
neurological) disease. The heatmap analysis also indicated that
certain immunophenotype subgroups discern between HD and
OND groups and patients with MS (RRMS and SPMS). In general,
two groups were formed: healthy donors on one side, and OND,
RRMS, and SPMS on the other. Differences could be identified in
the relative percentages of Treg cells, including CD3+CD4+/
CD25
high+/Foxp3+/CD27+CD28+ T-cells; increased percentages
could also be identified in TCRcd+/CD45RA2CCR7+ T-cells, in
TCRab+/CD8aa+/CD45RA2CCR7+ T-cells as well as in the
TCRab+/CD8aa+/CD45RA+CCR7+/CD272CD28+ T-cell
subset.
Differences in IL-7R density on immune cell subsets
Although we identified 19 significantly different immune
markers in PBMCs which allowed to segregate healthy individuals
and individuals with neurological disease, none of these markers
were associated with expression of the Il-7 receptor. The analysis
addressed only the percentage of Il-7R-positive T-cells in
lymphocytes, it reflected the relative composition of IL-7R+ cells
in PBMCs. Differences in immune cell subsets, as well as biological
responses may not only be associated with the relative distribution
of immune cells, but also with the absolute number of (IL-7R)
molecules on single cells. We extended therefore the analysis of
cellular immune abnormalities associated with CNS inflammation
to the number of Il-7R molecules on the single cell level. 59
immune cell subsets (listed in the supplementary Table S1 online,
S1.4) were examined for differences in IL-7 receptor densities. IL-
7R density was associated with physiological alterations in immune
cell subsets reflecting T-cell maturation/differentiation. Differen-
tiated T-cells, defined by the CD45RA+CCR72 phenotype,
exhibited the lowest number of IL-7 receptor molecules (Figure 4)
and central/peripheral memory T-cells (CD45RA2CCR7+ or
CD45RA2CCR72) exhibited the highest IL-7R density. Mean,
median values and standard deviation for the enumeration of Il-
7R molecules are provided for each of the 59 individual immune
cell subsets, segregated for each patient group and healthy donors
(Supplementary Table S2). We could not identify statistical
significant differences within these T-cell subsets, defined by
CD45RA and CCR7 expression, which segregate healthy
individuals and individuals with neurological diseases. However,
we could identify two immune cell subsets which showed
significant differences in IL-7R density on the single cell level. A
clear difference among PBMCs from healthy blood donors and
individuals with neurological diseases can be seen in the boxplots
of TCRab+CD4+CD252CD107a+CD127+ T-cells (p=0.0008)
and less clearly in TCRab+CD4+CD25
int+CD127+(p=0.043)
(Figure 5), the absolute number of events for each T-cell
population segregated by groups is provided in the supplementary
Table S3. With these two variables, the clustering of individuals
provided a rather good discrimination of PBMCs from healthy
individuals, less clear discrimination of OND and RRMS, and
none at all of SPMS based on heatmap cluster analysis (data not
shown). PBMCs from healthy donors showed 28664 (mean value)
IL-7R molecules on TCRab+CD4+CD252CD107a+CD127+ T-
cells, 50734 (mean value) molecules were observed on the same T-
cell subset in PBMCs from patients with RRMS, 40634 (mean
value) molecules were identified on TCRab+CD4+CD252C-
D107a+CD127+ T-cells from individuals with SPMS and 36331
(mean value) molecules were enumerated on this T-cell subsets in
PBMCs from patients with OND.
Discussion
Among 187 individual immune cell phenotypes, only a few
turned out to be statistically different in patients with MS as
compared to healthy controls. High content flow cytometric
analysis allows to analyze a plenitude of immune cell markers
visualizing changes in distinct immune cell subsets. Only the
combination of appropriate cell surface makers enabled us to
define differences in distinct immune cell subsets. For instance, a
population of of CD8
low+CD42 cells was recently identified in
Table 2. Age and Sex ratios/group.
HC Age Sex SPMS Age Sex RRMS Age Sex OND Age Sex
14 2F 1 4 5F 1 3 2F 1 3 9F
25 8F 2 6 0F 2 3 5F 2 2 6F
34 2F 3 6 2F 3 3 0F 3 4 6F
44 9F 4 5 7F 4 3 7F 4 6 6F
56 2F 5 6 2F 5 5 5F 5 4 4F
65 1M 6 6 2F 6 2 8F 6 4 3F
72 4M 7 4 4F 7 3 1F 7 3 9F
85 8M 8 6 8F 8 2 5M 8 3 4F
95 1M 9 4 3M 9 3 5M 9 2 7M
10 48 M 10 54 M median 32 median39
11 58 M 11 51 M
12 NA 12 59 M
13 NA 13 45 M
14 NA median57
15 NA
HC - Healthy Control.
SPMS - Secondary Progressive Multiple Sclerosis.
RRMS - Relapse and Remittent Multiple Sclerosis.
OND - Other Neurological Diseases.
F - Female.
M - Male.
doi:10.1371/journal.pone.0006534.t002
Il-7R Density in MS
PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e6534untreated RRMS patients, as well as in individuals with a clinically
isolated demyelation syndrome; these differences had been
attributed to a reduction in CD8
low+CD56+CD32 natural killer
cells [4]. A more detailed prospective study in twenty patients who
were observed longitudinally [3] showed significant differences in
ten lymphocyte subsets associated with active MS and these
markers included the innate and the adaptive arms, i.e.
TCRab+CD4+CCR72CD45RA2 T-cells, TCRcd+CCR5+ T-
cells and regulatory T-cells. If we exclude individual 45 (Figure 3)
which showed a very similar profile as compared to individuals
with neurological diseases, we could also identify reduced numbers
of TCRab+CD4+CD25
high+ T-cells (p=0.0008). The simulta-
neous analysis of multiple markers (i.e. TCRab, CD25, Foxp3,
CD27, CD28 and CD127) for Treg cells showed a relative
increase of TCRab+CD4+CD25
high+CD27+CD28+ T-cells with-
in the CD4+CD25
high+ T-cell population, as well as an increase of
CD3+CD4+CD25
int+Foxp3+CD27+CD28+ T-cells. These
CD4+ T-cell subsets suggest an enrichment of activated T-cells
with the CD27+,CD28+ phenotype since Foxp3 expression is not
only a marker of Treg cells, it also indicates T-cells activation: IL-
2, IL-15, as well as IL-7 are able to transiently induce Foxp3 in
CD4+CD252 effector T-cells [9].
The reduction of CD4+CD25
high T-cells was due to a reduction
in TCRab+CD4+CD25
high+ CD272CD28+ as well as in
CD3+CD4+CD25
high+Foxp3+CD272CD28+ T-cells. Of note,
the Treg subsets, which showed to be decreased in patients with
MS as compared to healthy individuals, expressed CD28 and
some Treg subsets expressed invariably CD27 (Figures 2 and 3)
consistent with the notion that CD28 engagement controls
homeostasis of CD4+CD25+ Treg cells [10]. A decrease of Treg
cells in the peripheral circulation has been described in patients
with MS [11], and in other autoimmune diseases, i.e. RA [12].
Natural regulatory T-cells express CD25 which resulted in the
differentiation of regulatory (CD25high), activated (CD25in-
termed) and ‘precursor’ CD4+CD25
low T-cells [13]. We did not
observe significant differences between healthy donors or patients
with neurological diseases in IL-7R (CD127+) frequency or
receptor density on Treg cells. Low CD127 expression, along
with high CD25 expression has been shown to better define Treg
cells as compared to T-cells which express FOXP3+:
CD4+CD25
high+CD127
low+ T-cells show highly suppressive activ-
ity [14,15]. Expression of CD127 is negatively associated with
FOXP3 due to promoter-interaction [16]. However, there is a
minor, yet detectable population in CD4+CD25
high+CD127+
cells, these T-cells showed higher proliferative capacity and
produced more IFNc and IL-2 as compared to cells from healthy
control individuals [17] suggesting an abnormal function of
CD4+CD25
high, CD127+ T-cells in patients with MS.
We observed an increase in the percentage of central memory
TCRab (CD45RA2CCR7+) in CD8ab+ and CD8aa+ T-cell
subsets. The latter immune cell population presents a distinct
memory T-cell subset, presumably associated with long-term
antigen exposure. CD8aa+ T-cells have been shown to be present
in chronic infections [18] and they are enriched in antigen specific
Figure 1. Boxplots of significant different frequencies of immune cells in healthy individuals versus patients with neurological
diseases. Peripheral blood mononuclear cells from 46 patients with multiple sclerosis (MS), 9 patients diagnosed with relapsing remitting MS
(RRMS), 13 with secondary progressive multiple sclerosis (SPMS), 9 with other neurological diseases (OND) and well as 15 healthy donors (HD) were
analyzed (prior to therapy) by 12 color flow cytometry (TCRab, TCRcd, CD4, CD8a, CD8b, CD45RA, CCR7, CD27, CD28, CD107a, CD127, CD14) in a
cross-sectional study to identify variables significantly different between controls (HD) and patients (OND, RRMS, SPMS). We analyzed 187 individual
immune cell subsets (percentages), 19/187 variables segregated PBMCs obtained from healthy individuals from individuals with neurological
diseases. We show 18/19 variables, the number of CD127+CD19+ B-cells proved also to be different in HDs versus patients with autoimmune disease
(data not shown).
doi:10.1371/journal.pone.0006534.g001
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primates after BCG vaccination [20]. The percentage of central
memory phenotype CD45RA2CCR72 cells was also statistically
significant increased in TCRcd+ T-cells in patients with MS,
consistent with earlier reports which showed increased TCRcd+
T-cells in target tissues [21]. CD8+ T-cells may show detrimental
immune effector functions and contribute to chronic inflammation
[22], yet they may also exert suppressive functions [23].
Noteworthy, anti.-CD25 included in our panel, or other T-cell
activation or differentiation makers, e.g. CD27 or CD28 did not
segregate CD8+ T-cell subsets in patients from MS versus healthy
individuals. Only the combinatory analysis of the CD8a and
CD8b chain along with CD45RA, CCR7+, CD27 and CD28
marker analysis was able to segregate CD8 phenotypes in patients
with MS from CD8+T-cells from healthy blood donors.
Although the IL-7R was recently incriminated as a marker for
increased risk to develop MS [24,25], we could not identify the IL-7R
i nt h ea n a l y s i so fi m m u n ec e l ls u b s ets as a discriminatory marker
between healthy individuals and patients with MS. Most flow
cytometric analyses measure the percentage of distinct immune cell
subset in the parental cell population. However, functional differences
in immune cells could also be associated with the density of certain
receptor molecules on the single cell level. Therefore, we measured the
absolute number of IL-7 receptor molecules on the single cell level on
59 individual immune cell subsets (see online supplementary Table
S2). The number of IL-7R molecules/cells showed a range between
30.000 to 50.000 molecules/cell in distinct immune cell subsets, the
range is dependent on T-cell maturation (Figure 4). Memory T-cells
show a higher IL-7R density as compared to effector T-cells (see
details in supplementary Table S2). Only 2/59 immune cell
phenotypes showed significant differences in the comparison of
PBMCs from healthy individuals and patients with neurological
diseases: TCRab+CD4+CD252CD107a+ T-cells expressed higher
n u m b e r so fI L - 7 Rm o l e c u l e sa sc o m p a r e dt oP B M C so b t a i n e df r o m
control individuals. Most likely, CD4+CD252 T-cells may represent
terminally differentiated CD4+ T-cells [9]. Although CD25 has not
been examined, a similar CD4+ T-cell phenotype was reported for
mature, human CMV-specific effector CD4+ T-cells: these T-cells
produce MIP-1b,T N F a and IFNc in the absence of IL-2 and exhibit
lytic activity associated with perforin and granzyme expression [26].
Analysis of CD107a and CD127 in PBMCs from patients with breast
cancer showed a trend, but not statistically solid differences, towards
Figure 2. Visualization of differences in immune cell frequencies using heatmaps. After quality data extraction and statistical analysis
(Kruskal-Wallis test, see material and methods), p-values were obtained and a cutoff of 0.05 was applied to obtain a subset of significant variables. The
final analysis included a principal component analysis (PCA) to study the correlation between the variables, and cluster analysis to see the connection
between variables and groups of patients. Lighter colors (white) represent higher standardized values and darker represent lower standardized values
(red) summarizing cellular immune phenotypes (percentages of immune cell subsets). The individual 45 (a healthy blood donor is included in the
analysis). This individual showed aberrant immune markers in PBMCs.
doi:10.1371/journal.pone.0006534.g002
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could show that CD4+ T-cells obtained from patients with breast
cancer exhibit a reduced responsiveness to IL-7, defined by statistically
reduced STAT-5 phosphorylation; these data suggested that
differences in IL-7R expression, on the single cell level, may indeed
translate into biologically relevant responses to IL-7 [27]. Future
functional studies which link IL-7–mediated cellular downstream
events to IL-7R density will aid to study the clinical significance of
increased Il-7R expression. Since CD4+CD252 T-cells represent
terminally differentiated (effector) T-cells, we postulate that chronic
antigenic exposure and prolonged inflammation may contribute to the
expansion of this subset in patients with MS. It is important to note
that CD107a positive T-cells show increased IL-7R numbers on the
single cell level (Figure 5). It remains to be shown whether co-
expression of CD107a and CD127 reflects a general feature of T-cells
with effector granules, or if the CD107a+CD127+ T-cell phenotype
represents a CD4+ T-cell population associated with autoimmune
diseases or chronic inflammatory processes: CD4+CD252 cells from
patients with SLE were shown to be less sensitive to Treg activity as
compared to T-cells from healthy controls [28]. and a more recent
study showed increased numbers of CD4+CD252Foxp3+ T-cells in
patients with new-onset lupus erythematosus [29]. We propose that
the TCRab+CD4+CD252CD107a+ T-cell subset, defined by
increased numbers of IL-7R molecules, represents a terminally
differentiated [9] CD4+ T-cell population with effector granules,
associated with chronic exposure to antigen stimulation.
Materials and Methods
Immune cell phenotyping
Blood was obtained from healthy, age and sex-matched blood
donors and from individuals with neurological diseases (listed in
detailed inTable 1 and 2)afterinformed consent (Diarynumber02-
548, dated 20.Nov.2002, ethical committee Stockholm). PBMCs
were isolated using Ficoll, frozen in 90% fetal calf serum and 10%
DMSO until analysis. The recovery was 89–97% and live
lymphocytes were gated on forwarded versus sidescatter plot using
flow cytometry. Three different mAb panels (supplementary Table
S1.1 and S1.2) were used to define immune cell subsets listed in the
supplementary Table S1 (S1.3 and S1.4). The antibody panel has
been and titrated and evaluated by testing each mAb alone, or in
combination with a mix of 11 corresponding monoclonal reagents,
then by simultaneous incubation with 2 antibodies, followed by
incubation with 10 reagents. The next step included testing of a mix
Figure 3. Visualization of differences in immune cell frequencies using heatmaps. Similar data analysis as in Figure 3, yet data from
individual 45 were excluded. This allowed to cluster immune markers obtained in PMBCs from healthy individuals and individuals with inflammatory
processes of the central nervous system. Lighter colors (white) represent higher standardized values and darker lower standardized values (red)
summarizing immune phenotypes. p values are provided (right).
doi:10.1371/journal.pone.0006534.g003
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resulted in the following protocol: 0.5 million PBMCs were first
stained with anti-CCR7 for 15 minutes at 4uC, followed by addition
of the 10 color antibody mix (designated as panel 1 and panel 2, see
Table) and incubated for 15 minutes at 4uC. The anti-CD27
antibody was then added to cells which were incubated at 4uC, for
15 minutes, followed by washing with 1 ml of PBS containing 0.1%
BSA. The cell pellet was resuspended in 200 ul of PBS (0.1%BSA).
Thefirstantibody panel(listed inthe supplementaryTable S1,S1.2)
wasused to define53 individualimmunecell subset(S1.3)andpanel
2 defined 86 subsets (S1.3) The third panel (supplementary Table
S1.2) was used to identify Treg cells yielding 44 individual immune
cell subsets: PBMCs were stained with cell surface marker
antibodies (panel 3) and incubated at 4uC for 15 minutes. PBMCs
were then washed immediately with FACS staining buffer (BD
Pharmingen, San Diego, USA) and fixed with 1 ml of 16Fix/Perm
buffer (Biolegend, San Diego, CA, USA ) at room temperature for
20 minutes followed by one washing step with FACS staining buffer
and one time with 16Permeabilization buffer (Biolegend). PBMCs
were resuspended in 1 ml of 16 permeabilization buffer and
incubated at room temperature for 15 minutes, followed by
centrifugation at 250 g for 5 minutes. The cell pellet was
resuspended in 100 ul of 16permeabilization buffer and the Alexa
488-conjugated anti-Foxp3 antibody was added, followed by an
incubation at room temperature in the dark for 30 minutes and
washed, resuspended the pellet in 100 ul of staining buffer. Flow
cytometric analysis was performed using a FACS Aria (BD
Biosciences, Immunocytometry, San Jose, USA) and data were
analyzed using FACS DIVA software (BD Biosciences). Results
were reported in an excel spreadsheets as percentage or number of
CD127-binding sites on individual immune cell subsets. Sequential
gating strategies are depicted, as a paradigm, in the supplementary
Figure S1. Freshly harvested PBMCs and the corresponding
frozen/thawed aliquots from three healthy blood donors were
analyzed for immune cell marker expression. Similar data were
obtained (data not shown) which corroborates that the flow
cytometric data are relevant for frozen as well as for freshly
harvested PBMCs. Note that the percentage of immune cells
relating to frequency in the parental population, is indicated with a
slash, i.e. TCRab+/CD4+CD25hi+/CD27+CD28+ or TCRab+/
CD4+CD25int+/Foxp3+/CD27+CD28+ cells.
IL-7R binding site analysis on a single cell level. The former
analyses defined percentages in individual immune cell subsets. In
order to define the absolute number of IL-7 receptor molecules on
immune cell subsets on a single cell level, we obtained a preparation
of the anti-IL-7 receptor alpha chain monoclonal mAb (clone
Figure 4. IL-7 receptor density is associated with T-cell maturation. IL-7 receptor molecules were enumerated on the single cell level in
PBMCs from healthy controls and from patients with neurological disorders. We could not identify significant differences in IL-7R expression in TCRab,
CD8ab, CD8aa, TCRcd or on TCRab+CD4+ T-cell subsets, therefore we show the data from all individuals enrolled in the study. T-cells with the
CD45RA2CCR7+ phenotype exhibit the highest density of IL-7R molecules, followed by CD45RA2CCR72 T-cells and CD45RA+CCR7+(precursor) T-
cells. Differentiated CD45RA+CCR72 exhibit the lowest number of IL-7R molecules. Mean and median for each T-cell subset clustered by patient
groups is provided in the supplementary Table S2. CD127 expression appears to be associated with T-cell maturation/differentiation.
doi:10.1371/journal.pone.0006534.g004
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determine antibody binding sites, since the APC fluorescence
intensity can be compared to the fluorescence intensity associated
with the defined number of APC molecules on beads (supplemen-
tary Figure S2). Blank beads were suspended in 0.5 ml of PBS and
instrument settings were adjusted using ‘blank beads’, followed by
addition of beads (Bangs Laboratories, Inc. Indianapolis, USA) with
three different APC fluorescent intensities which reflect the number
of molecules/bead, 10e5 events were aquired. One drop of blank
microspheres was resuspended in 0.5 ml of PBS and the flow rate
was adjusted to 100–200 beads per second. The live gate of singlets
was created on a forward versus sideward scatter dot plot and a
APC histogram which showed only cells within the live gate. APC-
beads with three different fluorescence intensities (reflecting the
number of APC molecules/beads) were added to the tube with
blank beads. A calibration plot was established using Quickcal
software (Bangs Laboratories, Inc. USA ) using the median channel
fluorescence intensity values for each bead population loaded with a
distinct number of APC molecules. All PBMC samples were run
with the same instrumentation settings. Antibody binding capacity
Figure 5. Significant differences in IL-7R densities in immune cell subsets. IL-7 receptor (CD127) density analysis was carried in 59 individual
immune phenotypes using a monoclonal anti-Il-7R antibody (clone R34.34) coupled to a single APC molecule in combination with an APC-bead array.
A non-parametric analysis of variance (Kruskal-Wallis test) was conducted in order to test for differences among the patient groups for each of the
variables. 2/59 variables showed increased numbers of IL-7R molecules on TCRab+CD4+CD25(intermed)+ T-cells and on
TCRab+CD4+CD252CD107a+ T-cells (mean: 28376 Il-7R binding sites on cells from HD, 48515 in patients with RRMS, 38195 in patients with
SPMS and 33692 IL-7 receptor binding sites on cells from patients with OND). Differences are visualized using a heatmap (top panel) and boxplots
(bottom panel). p values are provided.
doi:10.1371/journal.pone.0006534.g005
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(in APC molecules) of each immune cell subset using Quick Cal soft
using the beads-calibration plot.
Data management and data analysis
Data were originally compiled in excel files with different sheets
containing data for the variables tested. Each patient had a unique
identification code and the corresponding disease group. Analyses
were conducted separately for the immune phenotypes (percent-
ages for immune subsets) and the Il-7R density analysis. Quality
control of the data was performed by summary statistics to
detected anomalies in the data sets. Each individual variable was
tested for the null hypothesis of ‘no difference’ among the disease
groups using the non-parametric Kruskal-Wallis test. The
alternative hypothesis is that at least one disease group differed
from the other disease group (or the healthy control group). We
choose a non-parametric approach due to the small number of
individuals in each group. Given the limited data and thus low
statistical power, no further tests to identify the deviating group (or
groups) were conducted. Since a large number of tested were
conducted, i.e. multiple comparisons, we applied a method that
controls for false discovery rate (FDR) [30] and obtained new
adjusted p-values for each variable. The significance level was set
to 0.05. To visualize the results, boxplots for the significant
variables were drawn. We clustered the individuals based on their
values of the significant variables. The clustering algorithm was an
agglomerative hierarchical method based on Euclidean distance of
the average [31]. Heatmaps were produced to visualize the
clustering results (Alexander Ploner, unpublished: Heatplus: A
heatmap displaying covariates and coloring clusters, R package
version 1.6.0). The heatmaps displayed the flow cytometric
markers (in percentage of the parental T-cell population) for each
individual patient. First, the top and bottom 1 percent of the values
were trimmed to avoid extreme values, and then normalized for
each marker by subtracting the mean and divided by the standard
deviation. The values were represented on a 12-step equidistant
scale, lighter colors (white) represent higher standardized values
and darker colors (red) represent lower standardized values. All
analyses were carried out in the statistical language R, version
2.6.2. (http://www.R-project.org)
Supporting Information
Figure S1 Detailed gating strategies for T-cell subsets, including
Tregs.
Found at: doi:10.1371/journal.pone.0006534.s001 (0.07 MB
PDF)
Figure S2 Paradigm of IL-7R (CD127) enumeration on immune
cells. A. Cells from the lymphogate were subjected to further
gating (n=59 different subsets). The anti-IL-7 receptor alpha
chain monoclonal mAb (clone R34.34) labeled with a single APC
molecule was used to define CD127 antibody binding sites, since
the APC fluorescence intensity can be compared to the
fluorescence intensity associated with the defined number of
APC molecules on beads (middle panel) with different APC
molecules (top panel, right). A calibration plot was established
using Quickcal software V2.3 (Bangs Laboratories, Inc. USA)
using the median channel fluorescence intensity values for each
bead population loaded with a distinct number of APC molecules.
All PBMC samples were run with the same instrumentation
settings. Antibody binding capacity values per cell were deter-
mined using the median value of CD127 (in APC) of each immune
cell subset using Quick Cal soft using the beads calibration plot. B.
Although the number of CD127+ T-cells may be different, e.g.
lower in individuals with autoimmune disease, the expression of
CD127 molecules on single cells may be higher.
Found at: doi:10.1371/journal.pone.0006534.s002 (0.05 MB
PDF)
Table S1 Compilation of monoclonal antibodies and immune
cell subsets.
Found at: doi:10.1371/journal.pone.0006534.s003 (0.03 MB
PDF)
Table S2 Mean and Median values of IL-7 Receptor densities
on T-cell subsets
Found at: doi:10.1371/journal.pone.0006534.s004 (0.08 MB
PDF)
Table S3 Number of events (min-max) for TCRab+CD4+
CD252CD107a+CD127+ and TCRab+CD4+CD25intermed+
CD127+ T-cell subsets
Found at: doi:10.1371/journal.pone.0006534.s005 (0.02 MB
PDF)
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